As rumors of rescheduling grow more prominent, concerns about big pharma’s potential control over the industry are escalating. We invited Dr. Matt Moore back for a third time to shed light on the challenges and opportunities in the development and research of cannabinoid and psychedelic drugs.
For those unfamiliar with Dr. Moore, he is an accomplished scientist with extensive experience in the pharmaceutical, cannabis, and psychedelic industries, adept at managing projects from pre-clinical stages to post-approval.”
This week, we sit down with Dr. Matthew Moore to discuss.
- Does Big Pharma benefit from a rescheduling of Cannabis?
- Cannabinoid Clinical Trials, challenges, and opportunities
- Brian Johnson and Medicine 3.0
#ReschuedlingCannabis #clinicaltrials #personalizedmedicine
Follow us: Our Links.
At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.
8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain
The Dime is a top 5% most shared global podcast
The Dime is a top 50 Cannabis Podcast
Sign up for our playbook here:
🎥 YouTube: The Dime
📸 Instagram: The Dime
🐣 Twitter: Bryan Fields, Kellan Finney
